{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:37:48Z","timestamp":1776109068696,"version":"3.50.1"},"reference-count":18,"publisher":"American Diabetes Association","issue":"9","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>We studied the serum concentration of tumor necrosis factor receptor 2 (TNFR2) and the rate of renal decline, a measure of the intensity of the disease process leading to end-stage renal disease (ESRD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A cohort of 349 type 1 diabetic patients with proteinuria was followed for 5\u201318 years. Serum TNFR2, glycated hemoglobin A1c (HbA1c), and other characteristics were measured at enrollment. We used a novel analytic approach, a joint longitudinal-survival model, fitted to serial estimates of glomerular filtration rate (eGFR) based on serum creatinine (median seven per patient) and time to onset of ESRD (112 patients) to estimate the rate of renal decline (eGFR loss).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At enrollment, all patients had chronic kidney disease stage 1\u20133. The mean (\u00b1SD) rate of eGFR loss during 5\u201318 years of follow-up was \u22125.2 (\u00b14.9) mL\/min\/1.73 m2\/year. Serum TNFR2 was the strongest determinant of renal decline and ESRD risk (C-index 0.79). The rate of eGFR loss became steeper with rising concentration of TNFR2, and elevated HbA1c augmented the strength of this association (P = 0.030 for interaction). In patients with HbA1c \u226510.1% (87 mmol\/mol), the difference in the rate of eGFR loss between the first and fourth quartiles of TNFR2 was 5.4 mL\/min\/1.73 m2\/year, whereas it was only 1.9 in those with HbA1c &amp;lt;7.9% (63 mmol\/mol).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Circulating TNFR2 is a major determinant of renal decline in patients with type 1 diabetes and proteinuria. Elevated HbA1c magnifies its effect. Although the mechanisms of this synergism are unknown, our findings allow us to stratify patients according to risk of ESRD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc13-1983","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T03:58:29Z","timestamp":1401940709000},"page":"2601-2608","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":50,"title":["Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5\u201318 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria"],"prefix":"10.2337","volume":"37","author":[{"given":"Jan","family":"Skupien","sequence":"first","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Warram","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika A.","family":"Niewczas","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Gohda","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Malecki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josyf C.","family":"Mychaleckyj","sequence":"additional","affiliation":[{"name":"Center for Public Health Genomics, University of Virginia, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej T.","family":"Galecki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Division of Geriatric Medicine, University of Michigan Health System, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej S.","family":"Krolewski","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"2022051611020030800_B1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022051611020030800_B2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022051611020030800_B3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2010040354","article-title":"Risk for ESRD in type 1 diabetes remains high despite renoprotection","volume":"22","author":"Rosolowsky","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022051611020030800_B4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ki.2012.189","article-title":"The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease","volume":"82","author":"Skupien","year":"2012","journal-title":"Kidney Int"},{"key":"2022051611020030800_B5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biostatistics\/1.4.465","article-title":"Joint modelling of longitudinal measurements and event time data","volume":"1","author":"Henderson","year":"2000","journal-title":"Biostatistics"},{"key":"2022051611020030800_B6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1198\/0003130042854","article-title":"Separate and joint modeling of longitudinal and event time data using standard computer packages","volume":"58","author":"Guo","year":"2004","journal-title":"Am Stat"},{"key":"2022051611020030800_B7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"key":"2022051611020030800_B8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/sim.720","article-title":"Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease","volume":"20","author":"Schluchter","year":"2001","journal-title":"Stat Med"},{"key":"2022051611020030800_B9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022051611020030800_B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2215\/CJN.03010608","article-title":"Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes","volume":"4","author":"Niewczas","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022051611020030800_B11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/sim.4780130524","article-title":"Testing for differences in changes in the presence of censoring: parametric and non-parametric methods","volume":"13","author":"Wu","year":"1994","journal-title":"Stat Med"},{"key":"2022051611020030800_B12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2022051611020030800_B13"},{"key":"2022051611020030800_B14","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc12-2521","article-title":"Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects","volume":"36","author":"Lopes-Virella","year":"2013","journal-title":"Diabetes Care"},{"key":"2022051611020030800_B15","doi-asserted-by":"crossref","DOI":"10.2337\/dc13-0985","article-title":"Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria","author":"Krolewski","year":"2014","journal-title":"Diabetes Care"},{"key":"2022051611020030800_B16","article-title":"Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria","author":"Skupien","journal-title":"J Am Soc Nephrol"},{"key":"2022051611020030800_B17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"2022051611020030800_B18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/9\/2601\/486644\/2601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/9\/2601\/486644\/2601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:02:53Z","timestamp":1652698973000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/9\/2601\/29205\/Synergism-Between-Circulating-Tumor-Necrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,7]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-1983","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}